Arai T, Yamashita T, Urano T, Masunaga A, Itoyama S, Itoh K, Shiku H, Sugawara I
Department of Pathology, Saitama Medical Center, Saitama Medical School, Kawagoe, Japan.
Mod Pathol. 1995 Apr;8(3):252-6.
The nm23 gene product is a possible mediator of cancer invasion and metastasis, and has been divided into two distinct gene products, NM23-H1 and NM23-H2. It has been shown previously that expression of nm23-H1 messenger RNA is reduced in metastatic lymph nodes from patients with papillary carcinoma of the thyroid (Am J Pathol 142:1938-1944, 1993). Since mAb H1-229 specific for NM23-H1 is now available, we further extended our study to examine the expression of nm23-H1 gene product in various types of thyroid cancer (37 cases of papillary carcinoma, 42 cases of follicular carcinoma, 17 cases of anaplastic carcinoma, and 3 cases of medullary carcinoma). NM23-H1 was expressed in primary papillary and follicular carcinomas (14/15 and 21/22), but weakly or hardly expressed in metastatic lymph nodes and metastatic bone marrow (6/23 and 1/4) (P < 0.01). Expression of NM23-H1 was low or absent in anaplastic and medullary carcinoma (3/17 and 0/3) (P < 0.01).
nm23基因产物可能是癌症侵袭和转移的介质，已被分为两种不同的基因产物，即NM23-H1和NM23-H2。先前的研究表明，甲状腺乳头状癌患者转移淋巴结中nm23-H1信使核糖核酸的表达降低（《美国病理学杂志》142:1938 - 1944, 1993）。由于现在有了对NM23-H1特异的单克隆抗体H1-229，我们进一步扩展研究，以检测nm23-H1基因产物在各种类型甲状腺癌中的表达（37例乳头状癌、42例滤泡状癌、17例未分化癌和3例髓样癌）。NM23-H1在原发性乳头状癌和滤泡状癌中表达（14/15和21/22），但在转移淋巴结和转移骨髓中表达较弱或几乎不表达（6/23和1/4）（P < 0.01）。NM23-H1在未分化癌和髓样癌中表达低或无表达（3/17和0/3）（P < 0.01）。
